Core Viewpoint - The local alliance procurement system is expanding significantly, focusing on high clinical usage and market scale core products, creating a comprehensive procurement system that combines national and local characteristics [1][3]. Group 1: Local Alliance Procurement Developments - By the end of 2025, local alliance procurement will enter a concentrated implementation phase, with approximately 20 specialized national alliance procurements planned, including traditional Chinese medicine and high-value consumables [1]. - Recent local drug procurement initiatives include Henan's inter-provincial alliance procurement covering 34 high-demand products and the continuation of procurement in Hebei [1][4]. - The procurement in Hebei has reached a new scale, with 187 products included, featuring significant items like Silybin and Vitamin D, indicating a robust market response [4]. Group 2: Market Dynamics and Competitive Landscape - The current local procurement is characterized by a "precise strike" approach, focusing on core products with large clinical usage, which is expected to disrupt existing market structures [3]. - Major products included in the procurement have substantial sales figures, such as the Compound Fufang Fuke Ding Oral Liquid, which had a sales volume of 311 million yuan in 2024 [3]. - The competitive landscape is shifting from price wars to comprehensive strength battles, with companies needing to adapt their production lines and supply chains to maintain market share [2][6]. Group 3: Quality and Regulatory Changes - The procurement rules have been upgraded to emphasize quality, with a tiered quality assessment system being implemented in Henan and Hebei [6]. - The evaluation mechanism now includes a comprehensive scoring model that weighs economic and technical factors alongside pricing, promoting a fair competitive environment for quality-focused companies [6]. - The shift towards quality-driven competition is expected to phase out smaller companies that lack quality control capabilities, leading to increased industry concentration [4][6]. Group 4: Long-term Industry Implications - The ongoing procurement process is causing short-term pain for many listed pharmaceutical companies, with revenue and profit growth slowing down [7]. - Despite the immediate challenges, the long-term outlook suggests a transition towards high-quality development, moving away from marketing-driven models [7]. - The industry is likely to see a bifurcation where leading companies leverage their full supply chain advantages, while smaller firms focus on niche markets to build competitive strengths [7].